Henan Newland Pharmaceutical Co. Ltd. A Total Liabilities
Henan Newland Pharmaceutical Co. Ltd. A total liabilities. Based on the latest financial reports, Henan Newland Pharmaceutical Co. Ltd. A (301277) has total liabilities worth CN¥236.14 Million CNY (≈ $34.55 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check 301277 asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Henan Newland Pharmaceutical Co. Ltd. A (2020–2025)
Total liabilities of Henan Newland Pharmaceutical Co. Ltd. A from 2020 to 2025. This chart illustrates how Henan Newland Pharmaceutical Co. Ltd. A's total liabilities have evolved over time, based on quarterly financial data.
Henan Newland Pharmaceutical Co. Ltd. A Competitors by Total Liabilities
The table below lists competitors of Henan Newland Pharmaceutical Co. Ltd. A ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Veradigm Inc.
NASDAQ:MDRX
|
USA | $513.64 Million |
|
4D Molecular Therapeutics Inc
NASDAQ:FDMT
|
USA | $61.05 Million |
|
Shanghai New Centurion Network Information Technology Co Ltd
SHG:605398
|
China | CN¥152.67 Million |
|
Chang Jiang Shipping Group Phoenix Co Ltd
SHE:000520
|
China | CN¥379.41 Million |
|
Shenzhen Prince New Materials Co Ltd
SHE:002735
|
China | CN¥1.49 Billion |
|
Shenzhen Jasic Tech Co
SHE:300193
|
China | CN¥1.01 Billion |
|
Fujian Raynen Tech Co Ltd
SHG:603933
|
China | CN¥1.63 Billion |
|
Beijing Scitop Bio Tech Co Ltd
SHE:300858
|
China | CN¥236.16 Million |
Liability Composition Analysis (2020–2025)
This chart breaks down Henan Newland Pharmaceutical Co. Ltd. A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see 301277 total asset value.
Liquidity & Leverage Metrics
Henan Newland Pharmaceutical Co. Ltd. A Total Liabilities Ratios Explained
Henan Newland Pharmaceutical Co. Ltd. A total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.35 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.15 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.13 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Henan Newland Pharmaceutical Co. Ltd. A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Henan Newland Pharmaceutical Co. Ltd. A (2020–2025)
The table below shows the annual total liabilities of Henan Newland Pharmaceutical Co. Ltd. A from 2020 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥228.49 Million ≈ $33.44 Million |
-15.59% |
| 2024-12-31 | CN¥270.69 Million ≈ $39.61 Million |
+69.16% |
| 2023-12-31 | CN¥160.02 Million ≈ $23.42 Million |
-8.34% |
| 2022-12-31 | CN¥174.58 Million ≈ $25.55 Million |
-33.24% |
| 2021-12-31 | CN¥261.53 Million ≈ $38.27 Million |
+25.39% |
| 2020-12-31 | CN¥208.57 Million ≈ $30.52 Million |
-- |
About Henan Newland Pharmaceutical Co. Ltd. A
Newland Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical intermediates and APIs in China. The company offers pharmaceutical intermediates, including L-4-hydroxyphenylglycine methyl ester, L-hydroxyphenylglycine potassium salt, L-4-hydroxyphenylglycine, and p-Toluenesulfonic acid. It also provides APIs, such as ropivacaine hydrochloride, naph… Read more